TrialRespiratory research2020

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

Nicola C Day et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.